Literature DB >> 12115734

Progression elevated gene-3, PEG-3, induces genomic instability in rodent and human tumor cells.

Zao-Zhong Su1, Rahul V Gopalkrishnan, Gopeshwar Narayan, Paul Dent, Paul B Fisher.   

Abstract

Genomic instability is a fundamental component of cancer progression. Subtraction hybridization identified a novel rodent gene, progression elevated gene-3 (PEG-3) whose expression directly correlates with cancer aggressiveness and progression. Moreover, ectopic expression of PEG-3 in rodent or human tumor cells produces an aggressive transformed phenotype. We demonstrate that PEG-3 expression in rodent tumor cells correlates directly with genomic instability as characterized by alterations in chromosome composition and structure. Additionally, elevated endogenous or ectopic expression of PEG-3 in rodent and human tumor cells, respectively, enhances gene amplification, as monitored by resistance to methothrexate (MTX) and amplification of the dihydrofolate reductase (dhfr) gene. Stable expression of PEG-3 in normal cloned rat embryo fibroblast (CREF) cells marginally elevates MTX resistance, but morphology remains unaltered and anchorage independence is not induced, suggesting that these phenotypes are separable in immortal cells and gene amplification may precede the acquisition of morphological and oncogenic transformation. The present studies document that stable, inducible, and transient expression of PEG-3 in cancer cells augments genomic instability. In these contexts, one mechanism by which PEG-3 influences cancer progression may be by preferentially facilitating the development of genomic changes in evolving cancer cells. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115734     DOI: 10.1002/jcp.10114

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  4 in total

1.  Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter.

Authors:  Zhao-Zhong Su; Devanand Sarkar; Luni Emdad; Gregory J Duigou; Charles S H Young; Joy Ware; Aaron Randolph; Kristoffer Valerie; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

Review 2.  Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic.

Authors:  Rupesh Dash; Belal Azab; Xue-Ning Shen; Upneet K Sokhi; Siddik Sarkar; Zhao-zhong Su; Xiang-Yang Wang; Pier Paolo Claudio; Paul Dent; Igor P Dmitriev; David T Curiel; Steven Grant; Devanand Sarkar; Paul B Fisher
Journal:  Discov Med       Date:  2011-01       Impact factor: 2.970

Review 3.  Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.

Authors:  Swadesh K Das; Siddik Sarkar; Rupesh Dash; Paul Dent; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

4.  Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).

Authors:  Belal M Azab; Rupesh Dash; Swadesh K Das; Sujit K Bhutia; Siddik Sarkar; Xue-Ning Shen; Bridget A Quinn; Paul Dent; Igor P Dmitriev; Xiang-Yang Wang; David T Curiel; Maurizio Pellecchia; John C Reed; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2014-01       Impact factor: 6.384

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.